| Literature DB >> 31003398 |
Glauber V da Costa1,2,3, Elenilze F B Ferreira4,5, Ryan da S Ramos6, Luciane B da Silva7, Ester M F de Sá8, Alicia K P da Silva9, Cássio M Lobato10, Raimundo N P Souto11, Carlos Henrique T de P da Silva12, Leonardo B Federico13, Joaquín M C Rosa14, Cleydson B R Dos Santos15,16,17.
Abstract
Aedes aegypti (Linnaeus, 1762; Diptera: Culicidae) is the main vector transmitting viral diseases such as dengue fever, dengue haemorrhagic fever, urban yellow fever, zika and chikungunya. Worldwide, especially in the Americas and Brazil, many cases of dengue have been reported in recent years, which have shown significant growth. The main control strategy is the elimination of the vector, carried out through various education programs, to change human habits, but the most usual is biological control, together with environmental management and chemical control. The most commonly insecticide used is temephos (an organophosphorus compound), but Aedes aegypti populations have shown resistance and the product is highly toxic, so we chose it as a template molecule to perform a ligand-based virtual screening in the ChemBrigde (DIVERSet-CL subcollection) database, searching for derivatives with similarity in shape (ROCS) and electrostatic potential (EON). Thus, fourty-five molecules were filtered based on their pharmacokinetic and toxicological properties and 11 molecules were selected by a molecular docking study, including binding affinity and mode of interaction. The L46, L66 and L68 molecules show potential inhibitory activity for both the insect (-9.28, -10.08 and -6.78 Kcal/mol, respectively) and human (-6.05, 6.25 and 7.2 Kcal/mol respectively) enzymes, as well as the juvenile hormone protein (-9.2; -10.96 and -8.16 kcal/mol, respectively), showing a significant difference in comparison to the template molecule temephos. Molecules L46, L66 and L68 interacted with important amino acids at each catalytic site of the enzyme reported in the literature. Thus, the molecules here investigated are potential inhibitors for both the acetylcholinesterase enzymes and juvenile hormone protein-from insect and humans, characterizing them as a potential insecticide against the Aedes aegypti mosquito.Entities:
Keywords: acetylcholinesterase; juvenile hormone; molecular docking; temephos
Year: 2019 PMID: 31003398 PMCID: PMC6630876 DOI: 10.3390/ph12020061
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 12D-structural formula of the temephos molecule (O,O,O′,O′-tetramethyl-O,O′-sulfanediylbis(1,4-phenylene)).
Pharmacokinetic properties of selected molecules.
| Molecules | ID | Star a | CNS b | MW c | ClogP/ | log (BB) e | MDCK (nm/s) f | HBD g | HBA h | R5 i |
|---|---|---|---|---|---|---|---|---|---|---|
| Normal range | - | 0–5 | −2 to +2 | 130–725 | −2.0 to 6.5 | −3.0 to 1.2 | <25 poor, >500 great | 0–6 | 2–20 | Max. 4 |
| TRI (toxic) compounds l | - | - | - | - | −2.1 to 6.99 | −1.67 to 0.794 | 25.65 to 104 | 0–3 | 0–9.53 | - |
| Temephos | - | 5 | 0 | 466.458 | 7.333 | −0.491 | 104 | 0 | 3.00 | 1 |
| omega_22273_1_1_66 | L66 | 0 | 0 | 345.406 | 4.251 | −0.430 | 947.552 | 1 | 5.00 | 0 |
| omega_23792_1_1_68 | L68 | 0 | 0 | 350.425 | 3.507 | −0.656 | 563.417 | 1 | 6.50 | 0 |
| omega_32859_1_1_12 | L12 | 0 | 1 | 315.429 | 4.163 | 0.269 | 3898.807 | 0 | 3.75 | 0 |
| omega_5087_1_1_46 | L46 | 0 | 1 | 287.401 | 2.931 | 0.079 | 3128.836 | 0 | 4.70 | 0 |
| omega_36855_1_1_257 | L257 | 0 | 0 | 372.441 | 3.550 | −0.423 | 1578.497 | 0 | 7.20 | 0 |
| omega_31303_1_1_291 | L291 | 0 | 0 | 348.404 | 3.560 | −0.644 | 538.073 | 1 | 6.25 | 0 |
| omega_20865_1_1_102 | L102 | 0 | 1 | 282.401 | 2.380 | −0.049 | 3166.685 | 0 | 4.70 | 0 |
| omega_12589_1_1_18 | L18 | 0 | 0 | 381.474 | 3.147 | −0.425 | 696.935 | 0 | 7.50 | 0 |
| omega_45720_1_1_22 | L22 | 0 | 0 | 339,317 | 3.894 | −0.052 | 3333.563 | 1 | 5.70 | 0 |
| omega_28697_1_1_35 | L35 | 0 | 0 | 354.451 | 2.310 | −0.581 | 620.602 | 0 | 7.50 | 0 |
| omega_34836_1_1_50 | L50 | 0 | 0 | 341.452 | 2.661 | −0.581 | 648.835 | 1 | 6.50 | 0 |
[a] Number of computed properties which fall outside the required range for 95 % of known drug; [b] Activity in the central nervous system; [c] Molar weight; [d] partition coefficients for octanol/water; [e] Predicted brain/blood partition coefficient (f) cellular permeability, in nm/s, of two cell linesdMadin-Darby canine kidney (MDCK) cells (Affymax scale) (g) Number of hydrogen bonds donated by the molecule; [f] Number of hydrogen bonds accepted by the molecule; [i] Number of violations of Lipinski’s ‘Rule of Five’.
Figure 2Overlays of crystallographic ligands poses: in (A) I40 (in green), with the calculated pose (in yellow), in (B) GNT (in green) with the calculated pose (in yellow), and in (C), JHIII (in green) with the calculated pose (in yellow).
Figure 3Results of binding affinity of the compounds with insect acetylcholinesterase receptor.
Figure 4Results of binding affinity of the compounds with human acetylcholinesterase.
Figure 5Results of binding affinity of the compounds with the juvenile hormone receptor (PDB ID 5V13).
Figure 6Interactions of the active site of the insect acetylcholinesterase (Drosophila melanogaster) with the molecules L46 2D (A1) 3D (A2), molecules L66 2D (B1) 3D (B2) and molecules L68 2D (C1) 3D (C2).
Figure 7Interactions of the human acetylcholinesterase active site from Homo sapiens with molecules L46 2D (A1) 3D (A2), molecules L66 2D (B1) 3D (B2) and molecules L68 2D (C1) 3D (C2).
Figure 8Interactions of the juvenile hormone active site from Aedes aegypti with the molecules L46 2D (A1) 3D (A2), molecules L66 2D (B1) 3D (B2) and molecules L68 2D (C1) 3D (C2).
Interactions between the insect acetylcholinesterase and the most promising molecules.
| Molecular Docking | Residues | Distance (Å) | Type | ΔG |
|---|---|---|---|---|
| I40 vs PDB ID 1QON | Trp-83 | 4.1/4.497 | Pi-Alkyl | −12.66 |
| Trp-83 | 3.66/5.66 | Pi-Pi Stacked | ||
| His-480 | 2.75 | Conventional Hydrogen Bond | ||
| Phe-371 | 4.88 | Pi-Alkyl | ||
| Try-370 | 3.79/4.18 | Pi-Pi Stacked | ||
| Try-370 | 2.99 | Pi-donor | ||
| Try-374 | 4.34 | Pi-Alkyl | ||
| Try-71 | 4.49 | Pi-Pi Stacked | ||
| Try-71 | 3.98 | Pi-donor | ||
| L46 vs PDB ID 1QON | Trp-83 | 5.00 | Pi-Alkyl | −6.94 |
| Try-370 | 4.37 | Pi-T-Stacked | ||
| Try-370 | 3.26 | Carbon Hydrogen Bond | ||
| Try-71 | 5.41 | Pi-Alkyl | ||
| Phe-330 | 4.39 | Pi-Alkyl | ||
| Phe-371 | 5.41 | Pi-Alkyl | ||
| L66 vs PDB ID 1QON | Trp-83 | 4.41 | Pi-Pi-Stacked | −9.55 |
| Trp-83 | 4.65 | Pi-Alkyl | ||
| Try-370 | 5.98 | Pi-Pi-Stacked | ||
| Try-371 | 4.01 | Pi-Alkyl | ||
| Try-324 | 3.68 | Carbon Hydrogen Bond | ||
| Try-374 | 3.89 | Pi-Sigma | ||
| Phe-371 | 4.55 | Pi-T-Stacked | ||
| L68 vs PDB ID 1QON | Try-370 | 1.73 | Convent. Hydrogen Bond | −1.33 |
| Try-370 | 3.32 | Carbon Hydrogen Bond | ||
| Try-374 | 3.98 | Pi-Sigma | ||
| Try-371 | 4.01 | Pi-Alkyl | ||
| Glu-80 | 2.80 | Convent. Hydrogen Bond |
Interactions between the human acetylcholinesterase and the most promising molecules.
| Molecular Docking | Residues | Distance (Å) | Type | ΔG |
|---|---|---|---|---|
| GNT vs PDB ID 4EY6 | Trp-86 | 5.08/4.54/4.14 | Pi-Alkyl | −9.72 |
| Ser-203 | 2.61 | Conventional Hydrogen Bond | ||
| His-447 | 3.54 | Carbon Hydrogen Bond | ||
| Glu-202 | 2.31 | Conventional Hydrogen Bond | ||
| Tyr-337 | 5.45 | Pi-Alkyl | ||
| Tyr-124 | 3.73 | Carbon Hydrogen Bond | ||
| L46 vs PDB ID 4EY6 | Trp-86 | 4.30 | Pi-Alkyl | −7.64 |
| Trp-86 | 5.31 | Pi-Alkyl | ||
| Ser-125 | 2.78 | Carbon Hydrogen Bond | ||
| Tyr-124 | 2.65 | Conventional Hydrogen Bond | ||
| Trp-286 | 5.64 | Pi-Pi-T-Shaped | ||
| Ala-204 | 5.18 | Pi-Alkyl | ||
| Ser-203 | 2.78 | Pi-donor Hydrogen Bond | ||
| Tyr-337 | 2.66 | Carbon Hydrogen Bond | ||
| L66 vs PDB ID 4EY6 | Ser-203 | 2.93 | Pi-Donor | −3.88 |
| His-447 | 5.54 | Pi-T-Stacked | ||
| Tyr-124 | 2.91 | Pi-T-Stacked | ||
| Tyr-124 | 5.63 | Carbon Hydrogen Bond | ||
| Tyr-337 | 4.73 | Pi-Alkyl | ||
| Tyr-337 | 3.43 | Pi-Donor | ||
| Glu-202 | 2.72 | Conventional Hydrogen Bond | ||
| Phe-338 | 4.88 | Pi-Alkyl | ||
| Ala-204 | 4.09 | Pi-Alkyl | ||
| Ala-204 | 2.08 | Donor-Donor | ||
| L68 vs PDB ID 4EY6 | His-447 | 1.74 | Conventional Hydrogen Bond | −5.31 |
| Trp-86 | 4.80/5.28 | Pi-Alkyl | ||
| Trp-86 | 3.42/3.90 | Pi-T-Stacked | ||
| Try-337 | 2.97 | Carbon Hydrogen Bond | ||
| Glu-202 | 3.74 | Conventional Hydrogen Bond |
Interactions between the juvenile hormone and the most promising molecules.
| Molecular Docking | Residues | Distance (Å) | Type | ΔG |
|---|---|---|---|---|
| JHIII vs PDB ID 5V13 | Trp-53 | 4.53/4.95/5.02 | Pi-Alkyl | −5.61 |
| Val-51 | 4.74 | Alkyl | ||
| Leu-74 | 4.98 | Alkyl | ||
| Val-68 | 4.89 | Alkyl | ||
| Tyr-129 | 5.28/5.80 | Pi-Alkyl | ||
| Tyr-133 | 5.28/5.29 | Pi-Alkyl | ||
| Tyr-64 | 5.01 | Pi-Alkyl | ||
| Ile-140 | 4.98 | Alkyl | ||
| Phe-144 | 5.00 | Pi-Alkyl | ||
| L46 vs PDB ID 5V13 | Trp 53 | 4.12 | Pi-Alkyl | −8.46 |
| Trp 53 | 2.98 | Pi-Lone-Pair | ||
| Val-51 | 3.94 | Pi-Sigma | ||
| Val-68 | 3.93 | Alkyl | ||
| Val-65 | 3.65 | Alkyl | ||
| Ala-281 | 4.24 | Pi-Alkyl | ||
| Tyr-64 | 5.25 | Pi-Alkyl | ||
| Tyr-33 | 5.07 | Pi-Pi-Stacked | ||
| Tyr-33 | 4.40 | Pi-Alkyl | ||
| L66 vs PDB ID 5V13 | Trp-53 | 4.69/2.40 | Pi-T-Stacked | −10.56 |
| Val-51 | 4.94 | Pi-Alkyl | ||
| Val-51 | 3.72 | Pi-Sigma | ||
| Val-68 | 3.81/5.32 | Pi-Alkyl | ||
| Val-65 | 3.90 | Pi-Alkyl | ||
| Phe-144 | 5.24 | Pi-T-Stacked | ||
| Tyr-129 | 4.95 | Pi-T-Stacked | ||
| Tyr-129 | 3.23 | Pi-donor | ||
| Tyr-64 | 2.80/1.90 | Conventional Hydrogen Bond | ||
| Tyr-33 | 5.69/4.40 | Pi-Pi-Stacked | ||
| Ala-281 | 3.76 | Pi-Sigma | ||
| Leu-74 | 5.30 | Pi-Alkyl | ||
| L68 vs PDB ID 5V13 | Trp-53 | 3.83 | Pi-donor Hydrogen Bond | −8.70 |
| Pro-55 | 5.34 | Pi-Alkyl | ||
| Trp-50 | 2.99 | Pi-lone Pair | ||
| Val-68 | 3.93 | Alkyl | ||
| Val-65 | 4.35 | Alkyl | ||
| Tyr-64 | 4.67 | Alkyl | ||
| Ser-69 | 2.75 | Conventional Hydrogen Bond |
Figure 9Promising molecules L46 (A) and L66 (B) and L68 (C), selected by virtual screening.
Data from protocols used in the molecular docking validation.
| Receptor | Ligand | Ligand Coordinates of the Grid Center | Grid Size (Points) |
|---|---|---|---|
| AChE | 9-(3-Iodobenzylamino)-1,2,3,4-tetrahydroacridine | 74 | |
| AChE | (–)-Galantamine | 74 | |
| Juvenile hormone | Methyl(2 | 48 |